Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia

Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia

Abstract In 2017, the Food and Drug Administration (FDA) approved valbenazine and deutetrabenazine, two vesicular monoamine transporter 2 (VMAT2) inhibitors, as treatments for tardive dyskinesia (TD). Additionally, some trials have suggested that vitamin E may benefit TD patients. However, the mecha...

Full description

Saved in:
Bibliographic Details
Main Authors: Chao Li, Chuanjun Zhuo, Xiaoyan Ma, Ranli Li, Ximing Chen, Yachen Li, Qiuyu Zhang, Lei Yang, Hongjun Tian, Lina Wang
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Schizophrenia
Online Access:https://doi.org/10.1038/s41537-025-00618-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items